A thoughtful guide to NAD+ care.How we review
Menu

Follow the sources.

Provider advertising, clinical research, and geographic records play different roles in this publication. These notes make the distinction visible. The initial register was checked September 18, 2026; later source checks are dated in individual records. Current offers may change.

  1. FDA: questions and answers on dietary supplementsRegulatory categories and limits of premarket review.
  2. Martens et al. (2018): randomized oral NR crossover trialShort-term human biomarker and tolerability study; not a lifespan trial.
  3. Yoshino et al. (2021): NMN and muscle insulin sensitivitySmall randomized study in postmenopausal women with prediabetes; not evidence for NAD injections or general weight loss.
  4. OpenStax: energy in living systemsCoenzyme and redox chemistry, not treatment evidence.
  5. OpenStax: oxidative phosphorylationNADH and mitochondrial electron transport.
  6. PubChem: NAD chemical structure recordChemical identity; formula depends on the specified molecular form.
  7. NHS: understanding medical abbreviationsAbbreviations depend on clinical context; ask the author of a report to clarify.
  8. Trętowicz et al. (2026): whole-blood NAD and ageHuman study reporting no age-related whole-blood decline; does not measure every tissue.
  9. Human whole-blood NAD and aging (2022)Observational study with sex-related differences; not a dosing target.
  10. Dried blood spot measurement of NAD (2022)Analytical measurement research; assay validity is separate from clinical utility.
  11. Castro-Marrero et al. (2021): CoQ10 plus NADH in ME/CFSCombination trial in a specific diagnosed population; does not isolate NADH or establish NAD injection effects.
  12. CoQ10 plus NADH and exercise outcomes (2016)Randomized combination study in chronic fatigue syndrome.
  13. NR uptake and metastasis models (online 2022)Experimental cancer-model work; not a human cancer-risk estimate.
  14. Orr et al. (2023): NR in mild cognitive impairmentSmall randomized pilot of oral NR, distinct from NAD injections.
  15. Oral NR, cognition, and Alzheimer biomarkers (2025)Exploratory crossover study; not an established Alzheimer treatment.
  16. Phase II NR pilot in amnestic mild cognitive impairment (2026)Pilot trial; NAD biomarker increases did not establish improved principal cognitive outcomes.
  17. NR and cisplatin-induced neuropathy (2022)Preclinical research, not proof of nerve regeneration in consumers.
  18. Richie et al. (2015): oral glutathione randomized trialBody-store measurements; not a trial of combined NAD and glutathione injections.
  19. Comparative NAC and glutathione crossover study (2015)Oxidative-stress marker research; not proof of a NAD combination benefit.
  20. Dellinger et al. (2017): NR plus pterostilbene randomized trialCombination biomarker study with industry involvement; not a human longevity trial.
  21. Riche et al. (2014): pterostilbene metabolic-parameter trialA separate ingredient and population from an NR-only product.
  22. FDA: concerns with unapproved GLP-1 drugsQuality, identity, and dosing concerns; not a NAD combination efficacy study.
  23. FDA: compounding policies as GLP-1 supply stabilizesCurrent regulatory context; adding another ingredient does not create FDA approval.
  24. FDA: July 2026 compounding advisory committee materialsAgency evaluation includes MOTS-c-related substances and evidence gaps.
  25. FDA: frequently asked questions about animal drugsVeterinary drug categories and prescribing context.
  26. UC Davis: veterinary supplements and nutraceuticalsVeterinary supplement context; not a canine NAD efficacy trial.
  27. NCCIH: berberine and weight lossLimited oral evidence must not be transferred to patches.
  28. FDA: cosmetics labeling claimsDistinguishes appearance claims from drug claims.
  29. FDA: what you should know about eye dropsOphthalmic products require sterility; not evidence for NAD eye drops.
  30. Kind Patches: NAD+ product advertisingManufacturer claims, not independent clinical verification.
  31. UK ASA: Kind Patches ruling (2026)Advertising regulator found submitted evidence inadequate for the challenged claims; UK context, not an FDA action.
  32. Rho Nutrition: Liposomal NAD+Manufacturer label and billing terms; 100 mg NAD+ per 4 mL serving shown.
  33. Tru Niagen: 300 mg capsulesManufacturer label lists NR chloride; not direct NAD+.
  34. Life Extension: NAD+ Cell Regenerator and Resveratrol EliteManufacturer label and price snapshot; distinct from the plain NR formula.
  35. Life Extension: NAD+ Cell Regenerator 300 mgManufacturer product listing for the NR formula.
  36. Thorne: nicotinamide riboside ingredients and productsManufacturer describes NR hydrogen malate and related products.
  37. Cymbiotika: Liposomal NAD+Manufacturer describes a multi-ingredient packet; quality and benefit claims require separate evaluation.
  38. Quicksilver Scientific: NAD+ Gold 30 mLManufacturer describes NMN and refrigeration instructions despite the NAD product name.
  39. Renue By Science: NAD+ CompleteCurrent multi-ingredient label differs from some older listings; on-page starting prices vary.
  40. MitoQ: NAD+ Dual ActionManufacturer label contains niacinamide, NR, resveratrol, and PQQ.
  41. Qualia: NAD+ product pageManufacturer product and study claims; consult the current label and exact study design.
  42. Qualia: NAD+ ingredient discussionManufacturer explanation; not an independent comparison.
  43. Lumine Organics: NAD+ Renew product advertisingAdvertising uses NAD and NMN wording; exact active identity needs clarification.
  44. Aurevia Labs: NAD+ PerformanceOne of several similarly named sellers; identity must be matched to the actual order.
  45. Cata-Kor: NAD Core 250 mgManufacturer listing; confirm exact version and current label.
  46. Nutricost: NAD+ productManufacturer listing; separate from NMN and NAD-plus-resveratrol variants.
  47. Codeage: Liposomal NAD+ UltraManufacturer describes direct NAD plus several additional ingredients.
  48. Elysium: BasisManufacturer label for NR plus pterostilbene; claims and lot documentation are separate evidence.
  49. ProHealth: NAD Triple Boost with NMNManufacturer NMN formulation panel, revision 06.25; lists NMN, NMNH, and other ingredients, distinct from the NR version.
  50. Innerbody Labs: NAD+ SupportManufacturer page; related editorial content is not an independent comparison of its own product.
  51. Goli: Renew NAD+ gummiesManufacturer product advertising; format convenience is separate from efficacy.
  52. Force Factor: longevity collectionManufacturer lists multiple formats; match the exact product label.
  53. Eqqualberry: NAD+ Peptide Boosting SerumManufacturer cosmetic claims; does not isolate the effect of NAD.
  54. Numbuzin: No.9 NAD+ product setManufacturer product family; creams, toner, essence and patches differ.
  55. Medicube US: EGF NAD+ Firming SerumManufacturer cosmetic listing; not injectable or systemic-treatment evidence.
  56. Purito Seoul: product catalogOfficial catalog lists Retinol Retinal 2000 NAD+ Serum.
  57. Aramore: NAD topical and oral productsPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  58. JIYU: NAD moisturizing creamPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  59. BBB National Programs: Reus advertising decision, October 2025Primary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  60. NatureWise: official catalog, NAD+ Support ComplexPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  61. XKQ: NAD+ nicotinamide riboside listingPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  62. Selerb: Daily NAD+ for womenPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  63. Pure Health Max: NMN product explanationPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  64. Boostiva: product catalogPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  65. Happy Aging: NAD+ women longevity formulaPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  66. Tally Health: Super NADManufacturer bundle page: Super NAD combines the NAD+ niacinamide product with Restore. It is not an NR-only capsule. Checked September 18, 2026.
  67. Nature’s Fusions: Nutri Urolithin A diacetatePrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  68. Shed: NAD product discussionPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  69. The Vitamin Shoppe: NAD and NMN retail categoryPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  70. Qualia: manufacturer-reported controlled NAD studyPrimary product or publisher source; scope and verification limits are described in the article. Checked September 18, 2026.
  71. NYU: medical language processing abbreviation glossaryShows multiple clinical meanings for NAD; the author of a medical report should clarify the intended meaning.
  72. Liao et al. (2021): NMN and training in recreational runnersSix-week trial in 48 runners; selected threshold measures improved, without a corresponding VO2max benefit.
  73. McDermott et al. (2024): NICE randomized trial in peripheral artery diseaseDisease-specific walking trial; prespecified one-sided P < 0.10 threshold, not proof of athletic recovery.
  74. NMN timing, sleep, and fatigue randomized trial (2022)108 older adults; morning/afternoon NMN and placebo groups, with changes also seen in placebo groups.
  75. Morifuji et al. (2024): NMN, walking, and secondary sleep outcomes60 participants; primary stepping outcome did not differ. Sleep findings were secondary; manufacturer involvement.
  76. NHLBI: insomnia treatmentDescribes CBT-I as a usual first treatment for long-term insomnia; not evidence for NAD supplements.
  77. Dollerup et al. (2018): NR metabolic trial in men with obesity40 men, 12 weeks; no improvement in insulin sensitivity or reported glucose-metabolism measures.
  78. NIDDK: managing diabetesEstablished care context; no endorsement of NAD products as diabetes treatment.
  79. Brakedal et al. (2022): NADPARK phase I trial30 patients, 30 days, oral NR; early brain-NAD and metabolic findings do not establish slower progression.
  80. Berven et al. (2023): NR-SAFE Parkinson safety trial20 participants, four weeks; short-term safety and metabolic observations, not long-term efficacy.
  81. Neuro-SysMed: NOPARK study descriptionInvestigator protocol and endpoint description; not a published efficacy result.
  82. Wu et al. (2025): randomized NR trial in long COVID58 randomized; NAD increased without significant between-group symptom benefit. Exploratory analyses, dropout, and funding require context.
  83. CDC: long COVID clinical guidanceIndividual symptom management and post-exertional malaise context; not evidence of NAD treatment efficacy.
  84. NIAAA: alcohol use disorder, withdrawal, and recoveryWithdrawal can be life-threatening and needs risk-appropriate medical care; ongoing AUD treatment is a separate need.
  85. USP: dietary supplement verification summaryDescribes testing and auditing scope; quality verification is not proof of clinical benefit.
  86. FDA: mixing medications and dietary supplementsGeneral interaction and surgery guidance; specific risks must be matched to the actual ingredient and medication.
  87. FDA 101: dietary supplementsAdverse-event response and supplement safety context.
  88. Elysium: the science behind BasisManufacturer describes the studied NR and pterostilbene combination; interpretation checked against the original paper.
  89. Dellinger et al. (2017): randomized NR plus pterostilbene trialEight-week biomarker and safety study; lipid observations and baseline imbalance remain relevant.
  90. Holmes et al. (2026): open-label NRPT menopause pilot40 women, seven days, no randomized placebo comparison; manufacturer employees among authors.
  91. ProHealth: current NAD Triple Boost NR formulationManufacturer panel lists NR hydrogen malate plus NMNH and additional ingredients; distinct from the NMN version.
  92. NMNH as an NAD precursor in mammalian cells and mice (2021)Preclinical research; cannot establish clinical benefit or long-term safety of a retail human formulation.
  93. Strut Health: NAD+ TherapyProvider FAQ: one 500 mg vial for $149/month, including physician consultations and free shipping. Confirm the actual prescription and supplies. Refreshed September 19, 2026.
  94. Shed: NAD+ routes and pricesProvider lists nasal spray from $144/month and injections or oral tablets from $169/month. Checked September 18, 2026.
  95. Provn: NAD+ Injection plansProvider lists monthly-equivalent prices for several plan lengths; confirm upfront billing and cancellation treatment of active pharmacy orders. Checked September 18, 2026.
  96. NOVOS: Boost NMNManufacturer explicitly distinguishes NMN ingredient research from trials of the finished Boost product. Checked September 18, 2026.
  97. DoNotAge: Pure NMNManufacturer capsule and powder listing. Purity and testing statements have not been independently verified by this site. Checked September 18, 2026.
  98. Wonderfeel: Youngr NMNManufacturer lists amounts per capsule; its stated two-capsule use doubles those amounts. Checked September 18, 2026.
  99. Nuchido: TIME+ productManufacturer offer and current product information; compare the supplied formulation with the version studied. Checked September 18, 2026.
  100. Nuchido: ingredient explanationManufacturer identifies nicotinamide and additional botanical ingredients. Mechanism claims are not independent clinical verification. Checked September 18, 2026.
  101. Henderson et al. (2024): Nuchido TIME+ crossover trialSmall, company-involved biomarker study with 26 completers and 28-day intervention periods; not a lifespan trial. Checked September 18, 2026.
  102. Goli: Renew Supplement FactsLabel image inspected: two gummies, 50 mg NR chloride, 10 mg niacinamide, 30 mg vitamin C, and 4 g added sugar. Checked September 18, 2026.
  103. Force Factor: NAD+ Longevity capsulesManufacturer label distinguishes direct NAD+ and niacinamide from NR or NMN products. Checked September 18, 2026.
  104. Jarrow Formulas: NMN 125 mgManufacturer lists 60 tablets and one-tablet serving; suggested use also permits two tablets, changing bottle duration. Checked September 18, 2026.
  105. Solaray: NMNManufacturer listing: 500 mg per one-capsule serving, 60 capsules. Facility certification is not finished-product efficacy evidence. Checked September 18, 2026.
  106. ClinicalTrials.gov: UthPeak NMNH trial NCT06889740Registry and official API checked: completed, 80 participants, no results section posted at the time of review. Registration is not a favorable trial result. Checked September 18, 2026.
  107. AgelessRx: NAD+ Nasal SprayProvider lists $125/month subscription and $140 one-time purchase; customer check-ins are uncontrolled reports. Checked September 18, 2026.
  108. Force Factor: NAD+ Longevity Soft ChewsManufacturer describes a direct-NAD chew formula with CoQ10, PQQ, resveratrol, and niacinamide; distinct from its capsule formula. Checked September 18, 2026.
  109. Force Factor: NMN Longevity Soft ChewsManufacturer offers a separate NMN chew. Do not substitute another Force Factor label. Checked September 18, 2026.
  110. HHS: licensing across state linesExplains patient-location checks and several possible licensure pathways. This guidance does not establish any individual provider’s eligibility.
  111. Conze et al. (2019): NR dose-ranging trialEight-week trial of 100, 300, and 1,000 mg NR. The 100 mg blood-NAD result differed from baseline but not placebo; biomarker findings are not longevity outcomes.
  112. Okabe et al. (2022): 250 mg NMN trialThirty healthy adults, 250 mg NMN or placebo for 12 weeks. Whole-blood NAD and short-term observations; not a finished-product endorsement.
  113. MIB-626: microcrystalline NMN pharmacology trialSpecific formulation studied for 14 days in 32 older adults with overweight or obesity. Not a general retail dosing recommendation.
  114. 2026 human comparison of NR, NMN, and nicotinamideRandomized open-label 14-day study; 65 participants in the analysis. Comparable NR and NMN circulating-NAD responses do not establish long-term clinical equivalence.
  115. Tru Niagen Pro: 1,000 mg product and labelManufacturer panel: 1,000 mg nicotinamide riboside chloride per two-capsule serving. Product description is not independent efficacy verification.
  116. Codeage NAD+ Ultra: Supplement Facts panelManufacturer label viewed September 19, 2026: 500 mg direct NAD+ per three capsules, plus other active ingredients.
  117. DailyMed: Acetadote acetylcysteine prescribing informationOfficial labeling for a specific acetylcysteine medicine used in acetaminophen overdose. Not a general wellness or supplement claim.
  118. Renue: Pure NMN powder and batch resourcesManufacturer powder label and testing representations. Separate product from NAD+ Complete; 500 mg per labeled scoop.
  119. ProHealth: Uthever NMN Pro powder, 30 gramsManufacturer panel: 1,000 mg per level scoop and 30 servings. Not the brand’s Triple Boost capsule formula.
  120. TSA: medications in liquid formUS checkpoint guidance. Destination import rules, prescribing eligibility, and product storage require separate confirmation.
  121. BRAVO1 Wellness: NAD+ planProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  122. BRAVO1 Wellness: public laboratory document libraryProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  123. FDA: Compounding questions and answersPrimary reference; does not endorse the reviewed provider.
  124. FDA: Ingredients suitable for sterile compoundingPrimary reference; does not endorse the reviewed provider.
  125. NIH Office of Dietary Supplements: NiacinBackground on NAD and related nutrition; not a trial of this offer.
  126. Muscle Lab: clinic vitamin-drip booking and NAD shot add-onProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  127. Muscle Lab: mobile vitamin-drip booking and NAD shot add-onProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  128. PubChem: Nicotinamide adenine dinucleotidePrimary reference; does not endorse the reviewed provider.
  129. Grant et al. 2019: Human plasma and urine metabolome during NAD+ IV infusionPrimary reference; does not endorse the reviewed provider.
  130. FDA: Compounding questions and answersRegulatory context for compounded drugs.
  131. Drip Okoboji: current booking menuProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  132. Drip Okoboji: service descriptionsProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  133. Drip Okoboji: local appointments, payment and home visitsProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  134. NAD+ AT HOME: injection kitProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  135. NAD+ AT HOME: injection pen and full kitProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  136. NAD+ AT HOME: liposomal capsulesProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  137. NAD+ AT HOME: delivery policyProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  138. NAD+ AT HOME: pricing and billing policyProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  139. System Labs: NAD+ injection treatmentProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  140. System Labs: NAD+ nasal treatmentProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  141. System Labs: treatment catalogProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  142. System Labs: service and order termsProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  143. Velvet Rx: NAD+, sermorelin and GHK-Cu offersProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  144. Velvet Rx: terms of use and recurring billingProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  145. Trava: NAD+ injection offerProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  146. Trava: NAD+ nasal spray offerProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  147. Trava: care model and compounding disclosureProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  148. Brello Health: compounded NAD+ planProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  149. Brello Health: checkout and renewal termsProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  150. Good Life Meds: NAD+ injection and introductory promotionProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  151. Good Life Meds: NAD+ nasal spray specificationProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  152. Good Life Meds: treatment and care overviewProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  153. Shed: injection, nasal and oral NAD+ offersProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  154. CDC: Preventing unsafe injection practicesPrimary reference; does not endorse the reviewed provider.
  155. AgelessRx: NAD+ patch kit and quarterly planProvider statement, not independent verification of outcomes. Offer checked October 12, 2026.
  156. CoreAge Rx: NAD+ injectable product pageProvider advertising; $93 starting figure, not a complete combined-care quote. Checked October 15, 2026.
  157. CoreAge Rx: NAD+ nasal product pageSeparate administration route and provider claims. Checked October 15, 2026.
  158. CoreAge Rx: NAD+ offer pageOffer displays $99 and a full-refund claim that differs from the general policy. Checked October 16, 2026; no checkout completed.
  159. CoreAge Rx: semaglutide product pageProvider advertises a $79 starting monthly figure; not verified for every prescription or dose. Checked October 15, 2026.
  160. CoreAge Rx: tirzepatide product pageProvider advertises a $129 starting monthly figure; separate from NAD+ offerings. Checked October 15, 2026.
  161. CoreAge Rx: refund, subscription and shipping policyApproval and pharmacy-transmission finality, 30-day cutoff, consultation fees and renewal terms. Checked October 15, 2026.
  162. CoreAge Rx: contact and response-time informationBusiness-day support hours and stated response target; no response-time test. Checked October 15, 2026.
  163. FDA: Understanding the Risks of Compounded DrugsCompounded drugs are not FDA-approved and do not receive premarket review. Checked October 15, 2026.
  164. CoreAge Rx: current NAD+ offerProvider advertising; offer page displays $99/month. Checked September 19, 2026.
  165. CoreAge Rx: NAD+ Injectable product pageProvider advertising; product page displays a different starting price of $93/month.
  166. CoreAge Rx: NAD+ NasalProvider description of a different administration route.
  167. AgelessRx: NAD+ InjectionProvider product page. Customer surveys are not controlled clinical trials.
  168. AgelessRx: NAD+ offer and billing termsPromotional page contains multiple prices; verify selected plan and renewal.
  169. IVY RX: NAD+ InjectionProvider lists a starting price of $179 with use-varies wording and describes its testing process. Supply period requires confirmation.
  170. Eden: NAD+ InjectionProvider advertises $91 first-month medication plus required $39 first-month membership. Membership renews at $99/month; medication renewal remains separate and unconfirmed.
  171. Hone: Basic membership and medication costsProvider lists $165/month estimated NAD+ cost, $25/month membership, and a $25 onboarding fee. Optional consultation fees are separate.
  172. FDA: ingredients suitable for sterile compoundingSafety notice describing reported reactions and ingredient-quality concerns.
  173. FDA: compounding questions and answersExplains that compounded drugs are not FDA-approved.
  174. NIH Office of Dietary Supplements: niacinNutritional and biochemical context; not a clinical trial of NAD+ injections.
  175. Grant et al. (2019): NAD+ infusion metabolome pilotSmall human IV study; metabolic observations do not prove longevity or everyday benefits.
  176. Reyna et al. (2026): retrospective IV tolerability pilotRoute-specific retrospective tolerability evidence; not proof of effectiveness for home injections.
  177. FSMB: contact a state medical boardDirectory for checking clinician licensing with the relevant board.
  178. NABP: state boards of pharmacyDirectory for checking pharmacy credentials.
  179. US Census Bureau: 2025 Gazetteer filesPlace names, geographic identifiers, land areas and internal-point coordinates. Distances on this site are calculated straight-line estimates.
  180. Next Health: New York NAD+ therapyProvider advertises a New York City NAD+ service; inclusion is not independent clinical verification.
  181. SuperHealthy Rx: official nad pageOfficial page checked October 4, 2026; offer information is not outcome verification.